Selincro

This page shows the latest Selincro news and features for those working in and with pharma, biotech and healthcare.

Acorda acquires Biotie to expand in Parkinson's disease

Biotie also has a royalty stream from Lundbeck's sales of Selincro(nalmefene), which was launched in 2013 for the treatment of alcohol dependency.

Schultz takes Lundbeck helm after leaving Novo Nordisk

Newly launched alcohol dependency drug Selincro (nalmefene) added 41m kroner to the pot.
Brintellix first antidepressant with cognition claim in Europe

The Danish company also has a long-acting version of schizophrenia drug Abilify (aripiprazole) and alcohol addiction treatment Selincro (nalmefene) to help Brintellix return its revenues to growth.
NICE backs drug to cut alcohol consumption

NICE backs drug to cut alcohol consumption. Final guidance for Lundbeck’ s Selincro for use on NHS in England. ... NHS patients in England will now have access to Selincro (nalmefene), a once a day tablet marketed by Danish firm Lundbeck.
Lundbeck still feeling effects from Cipralex patent loss

There were also gains for Lundbeck's new schizophrenia drug Abilify Maintena (aripiprazole) - although the company did not reveal figures - and the start of contributions from alcohol dependency treatment Selincro (nalmefene)
NICE recommends Lundbeck’s alcohol dependency drug

NICE recommends Lundbeck’ s alcohol dependency drug. NHS patients to have access to Selincro to help control drinking. ... The importance of new products like Selincro became even more apparent over the summer following disappointing late-stage trial

More from news
Approximately 6 fully matching, plus 16 partially matching documents found.

Pharma deals during September 2012

The companies already have a worldwide exclusive licence agreement from 2006 for Selincro (nalmefene), a novel opioid system modulator to treat alcohol dependence. ... Lundbeck filed a marketing authorisation application for Selincro in the EU with

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

CHC hires first full-time account director

Newman will help manage Clark Health Communications' business in women's health and alcohol dependence, which includes the Communiqué Award-winning campaign for Lundbeck's Selincro (nalmefene).
Bayer’s Barbara Jaszewski joins Lundbeck

Jaszewski's most pressing task will be to lead the launch of Selincro (nalmefene), which was recently recommended by the European Medicines Agency (EMA) to treat alcohol dependence.
Lundbeck promotes Andreas Eggert and Klaus Abel to senior commercial roles

vortioxetine for major depression and Selincro (nalmefene) for alcohol dependence.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Add my company

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

No incentive for a cure: The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...